Drug Eluting Balloon Market Size (2024 - 2029)

Drug Eluting Balloon Market Analysis

The drug-eluting balloon market is expected to register an approximate CAGR of 18% during the forecast period.

COVID-19 had a significant impact on the growth of the market. The COVID-19 pandemic has negatively affected surgical procedures due to the high rate of infection and lockdown restrictions. A delay in diagnosis and treatments was also observed in patients with cardiovascular diseases as a result of a reduction of footfall in hospitals and diagnostic centers, which impacted the market studied as well. Such delay in diagnosis and treatment led to a slight decrease in the demand for drug-eluting balloons, thereby affecting the growth of the market. For instance, according to a research study published in NCBI in March 2022, there was a 52.7% reduction in the volume of adult cardiac surgeries and a 65.5% reduction in elective cases, which indicated the negative impact of COVID-19 on cardiac surgical procedures. However, another NCBI research study published in April 2021 stated that COVID-19 could increase the development of atherosclerosis due to ACE2, which is also a receptor for the SARS-CoV-2 virus. Thus, the long-term effect of COVID-19 on the human body may increase the prevalence of atherosclerosis and other cardiac diseases, which is expected to increase the demand for drug-eluting balloons, thereby by contributing to the growth of the market.

The increasing incidence of coronary and peripheral artery diseases around the world is expected to boost the market's growth. In addition, increasing research and development supported by government and private institutions and continuous initiatives about awareness regarding heart diseases are fuelling the market growth.

According to the Australian Institute of Health and Welfare, in May 2022, out of 11.8 million admissions, 7.0% of hospitalizations involved a stay in the intensive care unit, and 3.8% of hospitalizations involved cardiovascular diseases. According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Moreover, the increasing geriatric population, which is prone to cardiovascular diseases, and growing healthcare spending are projected to bolster market growth. For instance, according to the research study published in December 2021, by Elsevier, for older people aged 45 and above, the overall self-reported prevalence of diagnosed cardiovascular diseases (CVDs) was 29.4%. The prevalence rate increased with age, from 22% in the 45-54 age group to 38% in the 70+ age group, showing that the senior population is at high risk of having CVDs. Such prevalence of various cardiovascular conditions is expected to drive the demand for drug-eluting balloons as they are used to treat various cardiovascular conditions, thereby helping in the recovery of affected patients.

However, the high cost of development and commercialization of drug-eluting balloons, coupled with stringent regulatory procedures, are hampering the market growth.

Drug Eluting Balloon Industry Segmentation

Drug-eluting balloons are semi-compliant angioplasty balloons that are used to elute the drug in the targeted vessel. Drug-eluting balloons may be coated or non-coated. 

The drug-eluting balloon market is segmented by product (coronary drug-eluting balloon, peripheral drug-eluting balloon, and other products (renal/urology)), technology (FreePac, TransPac, EnduraCoat, and other technologies), end users (hospitals, ambulatory surgical centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also provides the estimated market sizes and trends for 17 different countries. The report offers the value (in USD million) for the above segments.